Details for Patent: 8,840,866
✉ Email this page to a colleague
Title: | Styrylpyridine derivatives and their use for binding and imaging amyloid plaques |
Abstract: | This invention relates to a method of imaging amyloid deposits and to styrylpyridine compounds, and methods of making radiolabeled styrylpyridine compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits. |
Inventor(s): | Kung; Hank F. (Springfield, PA), Kung; Mei-Ping (Wynnewood, PA) |
Assignee: | The Trustees of the University of Pennsylvania (Philadelphia, PA) |
Filing Date: | Jan 07, 2013 |
Application Number: | 13/735,609 |
Claims: | 1. A compound of Formula I ##STR00039## or a pharmaceutically acceptable salt thereof; wherein n is an integer from one to six; A.sub.4 is N; A.sub.1, A.sub.2, A.sub.3, and A.sub.5 are independently --CH, or --CR.sup.2, as permitted; R.sup.1 is: --(CH.sub.2).sub.pNR.sup.aR.sup.b, wherein R.sup.a and R.sup.b are independently hydrogen, ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl hydroxy(C.sub.1-4)alkyl or halo(C.sub.1-4)alkyl, and p is an integer from 0 to 5; hydroxy, (C.sub.1-4) alkoxy, hydroxy(C.sub.1-4)alkyl, halogen, cyano, nitro, (C.sub.1-4)alkyl, halo(C.sub.1-4)alkyl, formyl, --NHCO(C.sub.1-4 alkyl), or --OCO(C.sub.1-4 alkyl); R.sup.2 is: ##STR00040## wherein, q is an integer from 1 to 10, Rx and Ry are hydrogen, hydroxy or C.sub.1-4 alkyl; t is 0, 1, 2 or 3; Z is hydroxy, halogen, benzoyloxy substituted with halogen, benzyloxy substituted with halogen, phenyl(C.sub.1-4)alkyl substituted with halogen, aryloxy substituted with halogen, or a C.sub.6-10 aryl substituted with halogen; and R.sup.30, R.sup.31, R.sup.32 and R.sup.33 are in each instance independently hydrogen, hydroxy, C.sub.1-4 alkoxy, C.sub.1-4 alkyl, or hydroxy(C.sub.1-4alkyl; ##STR00041## wherein Rx and Ry are hydrogen, hydroxy or C.sub.1-4 alkyl; t is 0, 1, 2 or 3; Y is halogen, benzoyloxy substituted with halogen, phenyl(C.sub.1-4)alkyl substituted with halogen, aryloxy substituted with halogen, or C.sub.6-10 aryl substituted with halogen; U is hydrogen, hydroxy, halogen, benzoyloxy substituted with halogen, phenyl(C.sub.1-4)alkyl substituted with halogen, aryloxy substituted with halogen, or C.sub.6-10 aryl substituted with halogen; and R.sup.34, R.sup.35, R.sup.36, R.sup.37, R.sup.38, R.sup.39 and R.sup.40 are in each instance independently hydrogen, halogen, hydroxy, C.sub.1-4 alkoxy, C.sub.1-4 alkyl, or hydroxy(C.sub.1-4)alkyl; iii. NR'R'', wherein at least one of R' and R'' is (CH.sub.2).sub.dX, where X is halogen, and d is an integer from 1 to 4; the other of R' and R'' is hydrogen, C.sub.1-4-alkyl, halo(C.sub.1-4)alkyl, or hydroxy(C.sub.1-4alkyl; iv. halo(C.sub.1-4)alkyl; or v. an ether having the structure: [halo(C.sub.1-4)alkyl-O--(C.sub.1-4)alkyl]-; and R.sup.7 and R.sup.8 are each hydrogen. 2. The compound of claim 1 wherein R.sup.1 is hydroxy or --(CH.sub.2).sub.pNR.sup.aR.sup.b, wherein p is an integer from 0 to 5, and R.sup.a and R.sup.b are each independently hydrogen, ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl, or (CH.sub.2).sub.dX, where X is halogen, and d is an integer from 1 to 4, R.sup.2 is ##STR00042## wherein t is 0; ##STR00043## wherein t is 0; iii. NR'R''; iv. halo(C.sub.1-4)alkyl; or v. an ether having the structure: [halo(C.sub.1-4)alkyl-O--(C.sub.1-4)alkyl]-. 3. The compound of claim 1, wherein n is one. 4. The compound of claim 1, wherein at least one halogen is a radiohalogen. 5. The compound of claim 1, wherein at least one halogen is I, .sup.123I, .sup.125I, .sup.131I, .sup.76Br, .sup.77Br, F or .sup.18F. 6. The compound of claim 5, wherein R.sup.1 is --(CH.sub.2).sub.pNR.sup.aR.sup.b, wherein R.sup.a and R.sup.b are each independently hydrogen, ethyl, propyl, isopropyl, butyl, or t-butyl, isobutyl and p is 0. 7. The compound of claim 6, wherein R.sup.2 is ##STR00044## wherein t is 0. 8. The compound of claim 7, wherein q is an integer from 1 to 5. 9. The compound of claim 8, wherein R.sup.30, R.sup.31, R.sup.32 and R.sup.33 are each hydrogen. 10. The compound of claim 9, having the formula: ##STR00045## wherein, R.sup.a and R.sup.b are each independently hydrogen, ethyl, propyl, isopropyl, butyl, t-butyl, or isobutyl and Z is I, .sup.123I, .sup.125I, .sup.131I, Br, .sup.76Br, .sup.77Br, F or .sup.18F. 11. The compound of claim 6, wherein R.sup.2 is ##STR00046## wherein t is 0 and Z is hydroxy. 12. The compound of claim 11, wherein q is an integer from 1 to 5. 13. The compound of claim 12, wherein R.sup.30, R.sup.31, R.sup.32 and R.sup.33 are each hydrogen, and q is 1, 2 or 3. 14. The compound of claim 6, wherein R.sup.2 is ##STR00047## wherein t is 0 and U is hydroxy. 15. The compound of claim 14, wherein R.sup.34, R.sup.35, R.sup.36 and R.sup.37, R.sup.38, R.sup.39 and R.sup.40 are each hydrogen. 16. The compound of claim 14, having the formula: ##STR00048## wherein R.sup.a and R.sup.b are each independently hydrogen, ethyl, propyl, isopropyl, butyl, t-butyl, or isobutyl. 17. A composition comprising a compound according to claim 1 wherein said compound comprises a .sup.11C isotope, said isotope present in an amount above natural abundance, and said compound containing said .sup.11C isotope having a specific activity above background level. 18. A compound of Formula Ia: ##STR00049## wherein A.sub.4 is N and A.sub.1, A.sub.2, A.sub.3, and A.sub.5 are --CH or C--(O--CH.sub.2CH.sub.2).sub.qX as permitted; q is an integer from 1 to 10; R' and R'' are each independently hydrogen, ethyl, propyl, isopropyl, butyl, t-butyl, or isobutyl and X is a radiohalogen. 19. The compound of claim 18, wherein one of R' and R'' is hydrogen, the other is ethyl, propyl, isopropyl, butyl, t-butyl or isobutyl. 20. A pharmaceutical composition comprising a compound of any one of claim 1 or 18 and a pharmaceutically acceptable carrier or diluent. 21. A diagnostic composition for imaging amyloid deposits, comprising a radiolabeled compound of any one of claim 1 or 18 and a pharmaceutically acceptable carrier or diluent. 22. A method of imaging amyloid deposits in a mammal, comprising: a. introducing into the mammal a detectable quantity of a diagnostic composition of claim 21; b. allowing sufficient time for the labeled compound to be associated with amyloid deposits; and c. detecting the labeled compound associated with one or more amyloid deposits. |